Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

IncyteCARES for Jakafi is a program for residents
of the United States and Puerto Rico.

Understanding Your Coverage
for Jakafi® (ruxolitinib)

Graphic of phone support person Graphic of phone support person Graphic of phone support person

When you have a new prescription or a new insurance plan, navigating the details of what’s covered can be stressful. IncyteCARES for Jakafi can help walk you through these challenges. When eligible patients enroll in IncyteCARES for Jakafi, our team can work with you and your Healthcare Professional’s office to get the information you need on coverage and costs. We may also be able to help with information on certain insurance requirements or challenges that sometimes arise—so you can focus on taking care of yourself.

Confirming Your Coverage for Jakafi

Once we receive your prescription and insurance information, IncyteCARES for Jakafi can contact your insurance company to:

  • Find out if your plan will cover Jakafi and how much you may need to pay out of pocket
  • Determine which specialty pharmacies you can use to fill your Jakafi prescription
  • Identify any special steps your insurer may require, such as a prior authorization before coverage will be approved

These steps usually take up to 2 business days. Once we have the information, IncyteCARES for Jakafi will call you to review it. If needed, we can also discuss financial assistance options that may be available to you.

Help When Prior Authorization Is Required

Some insurance plans require a prior authorization before they will approve coverage for certain prescription medicines. This means they require your Healthcare Professional to give them more information about your health condition and why Jakafi has been prescribed before they will approve it for coverage. Some insurance plans call this process precertification, prior approval, or something similar. It can sometimes delay how quickly you can fill your Jakafi prescription.

If your plan requires a prior authorization for Jakafi, IncyteCARES for Jakafi can help by tracking and following up on any additional information your plan asked your Healthcare Professional to provide—so you and your Healthcare Professional can find out their decision quickly.

Appealing Your Insurer's Decision on Jakafi Coverage

Sometimes, an insurance company may refuse to cover a patient’s treatment with Jakafi. By law, the insurer must notify you in writing within a set amount of time to explain why coverage was denied. You also have the right to appeal the insurance company’s decision and have it reviewed by an independent third party. IncyteCARES for Jakafi can provide information to you and your Healthcare Professional about the appeals process if needed.

Temporary Supply of Medicine for Eligible Patients When Coverage Is Delayed

Eligible patients who have been prescribed Jakafi for an FDA-approved use and who are experiencing an insurance coverage delay may be able to receive a free short-term supply of Jakafi. Specific terms and conditions apply to qualify for this program. Learn more.


Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.


Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, or white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.